½ÃÀ庸°í¼­
»óǰÄÚµå
1420161

Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå ¿¹Ãø - Áö¿ª ºÐ¼® : Æ®·¹À̼­ À¯Çüº°, °Ë»ç À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°(-2030³â)

South & Central America Radioactive Tracer Market Forecast to 2030 - Regional Analysis - by Tracer Type, Test Type, Application, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 113 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀåÀº 2022³â¿¡ 4¾ï 7,696¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡´Â 16¾ï 3,433¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í, 2022³âºÎÅÍ 2030³â±îÁö CAGRÀº 16.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

¾Ï Áø´Ü¿¡¼­ ¹æ»ç¼º Æ®·¹À̼­ÀÇ »ç¿ëÀº Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀåÀ» ºÎÃß±é´Ï´Ù.

¾Ï ȯÀÚ´Â ¼¼°èÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, ÇコÄÉ¾î ºÐ¾ß¿¡¼­ÀÇ Á¾¾çÇÐÀº ÇöÀúÇÏ°Ô ¹ßÀüÇϰí ÀÖ´Â ºÐ¾ßÀÔ´Ï´Ù. Institute for Health Metrics and Evaluation(IHME)¿¡ µû¸£¸é ¾ÏÀº ½ÉÇ÷°ü Àå¾Ö¿¡ ÀÌÀº µÎ ¹øÂ° ÁÖ¿ä »çÀÎÀÔ´Ï´Ù. ¾ÏÀÇ Áø´Ü°ú Ä¡·á¿¡¼­ ÷´Ü Àç·á ¹× ¾à¹°ÀÇ »ç¿ëÀº Á¾¾çÇÐÀÇ ÇöÀúÇÑ ¹ßÀü°ú ÇÔ²² ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¹æ»ç¼º Æ®·¹À̼­¸¦ ÀÌ¿ëÇÑ ¿µ»ó Áø´ÜÀº Àü¸³¼± ¾Ï, ºÎÀΰú ¾Ï, Ç÷¾×À» ÅëÇÑ ¾Ï µî ¾ÏÀÇ À¯ÇüÀ» Á¤È®ÇÏ°Ô Áø´ÜÇϱâ À§ÇØ »ç¿ëµÇ´Â °í±Þ Áø´Ü¹ý Áß ÇϳªÀÔ´Ï´Ù. ü³»¿¡ ÁÖÀÔµÈ ¹æ»ç¼º Æ®·¹À̼­´Â ¾Ï ƯÀ¯ÀÇ ºÎÀ§¿¡ ºÎÂøÇÏ¿© ¾ÏÀÇ À¯ÇüÀ» Á¤È®ÇÏ°Ô Áø´ÜÇÕ´Ï´Ù. Æ®·¹À̼­´Â ¶ÇÇÑ ¾ÏÀÇ ¹ß´Þ ´Ü°è¸¦ °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µÇ¸ç ´ëºÎºÐÀÇ °æ¿ì È¿°úÀûÀÎ Ä¡·á¿Í ´õ ºü¸¥ ȸº¹À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. PET¿Í SPECT´Â Á¾¾ç °ËÃâ¿¡ °¨¸¶¼± ¹æÃâ ÇÙÁ¾À» »ç¿ëÇÏ´Â ÇÙ ¿µ»ó ¹æ¹ý Áß ÇϳªÀÔ´Ï´Ù. Á¾¾çÀÌ ¼ºÀåÇÔ¿¡ µû¶ó PET¿Í SPECTÀÇ Á¢ÇÕü·ÎÀÇ Èí¼ö°¡ ½Ã°£ÀÌ Áö³²¿¡ µû¶ó Áõ°¡Çϰí ÇÙ ¿µ»ó ¾à¹°ÀÇ Á¸Àç·Î ´ëºñ°¡ Çâ»óµË´Ï´Ù. ÀÌ·¸°Ô Çϸé Ç÷¾× Ŭ¸®¾î·±½º°¡ ÃËÁøµÇ°í ¼±¸íÇÑ Áø´Ü À̹ÌÁö¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ¾Ï °ËÃâ¿¡ °¡Àå ¸¹ÀÌ »ç¿ëµÇ´Â ¹æ»ç¼º Æ®·¹À̼­´Â F-18 Ç÷ç¿À·Îµ¥¿Á½Ã±Û·çÄÚ½º(18F-FDG)·Î Æ÷µµ´ç ¹× ¼³ÅÁ°ú ºñ½ÁÇÑ È­ÇÕ¹°ÀÔ´Ï´Ù. ¾Ï¼¼Æ÷´Â ¸Å¿ì Ȱ¹ßÇϸç Á¤»ó¼¼Æ÷º¸´Ù ¸¹Àº ¿¡³ÊÁö, Áï ¿©ºÐÀÇ Æ÷µµ´çÀ» ÇÊ¿ä·Î ÇÕ´Ï´Ù. PET ¹× SPECT¿Í °°Àº ¿µ»ó ÀåÄ¡´Â FDG°¡ ¹æÃâÇÏ´Â ÀÌ ¿¡³ÊÁö¸¦ °¨ÁöÇÏ¿© ½Åü¿¡¼­ ¹æ»ç¼º Æ®·¹À̼­ÀÇ À§Ä¡¸¦ ³ªÅ¸³»´Â À̹ÌÁö¸¦ ¸¸µì´Ï´Ù. À̸¦ ÅëÇØ ȯÀÚÀÇ ½Åü¿¡¼­ ¾Ï¼¼Æ÷ÀÇ À§Ä¡¸¦ È®ÀÎÇÏ°í ¾ÏÀÇ À¯Çü°ú º´±â¿¡ µû¶ó Ä¡·á¸¦ Á¶Á¤ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ¿Í °°ÀÌ ¾Ï Áø´Ü¿¡¼­ ¹æ»ç¼º Æ®·¹À̼­ÀÇ »ç¿ë Áõ°¡´Â ÃßÁ¤±â°£ µ¿¾È ½ÃÀå È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå °³¿ä

Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀåÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª ¹× ±âŸ Áß³²¹Ì·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀåÀº ¾Ï ȯÀÚ Áõ°¡, Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê °íÁ¶, ¹æ»ç¼º Æ®·¹À̼­ ¿¬±¸°³¹ßÀÇ °íÁ¶¿¡ ÀÇÇØ ¼ºÀåÀÌ Àü¸ÁµÇ°í ÀÖ½À´Ï´Ù.

Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(±Ý¾×)(-2030³â)

Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå ¼¼ºÐÈ­

Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀåÀº Æ®·¹À̼­ À¯Çüº°, °Ë»ç À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, ¿ëµµº°, ±¹°¡º°¿¡ µû¶ó ±¸ºÐµË´Ï´Ù. Æ®·¹À̼­ À¯Çüº°·Î Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀåÀº Å×Å©³×Ƭ-99m&Tc-97m, ¿ä¿Àµå 131, ö-59, ·çÅׯ¬-171, ¿°È­·çºñµã(Rb-82)&¾Ï¸ð´Ï¾Æ(N-13), ½ºÄ­µã-46, ½Ãº¸±â¿ò-269, Çì½·-269·Î ±¸ºÐµÇ´Â ±¸¿¬»ê °¥·ý Ga 67, Àü¸³¼± ƯÀÌÀû ¸· Ç׿ø(PSMA)(Ga-68), FDDNP(F-18) ¹× FDOPA(F-18), ÀÎ-32 ¹× Å©·Ò-51, Å»·ý-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE(Ga-68), ±âŸ. 2022³â¿¡´Â ±âŸ ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

°Ë»ç À¯Çüº°·Î º¸¸é Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀåÀº PET, SPECT µîÀ¸·Î ±¸ºÐµË´Ï´Ù. PET ºÐ¾ß°¡ 2022³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, Áø´Ü¼¾ÅÍ, Çмú ¹× ¿¬±¸ ±â°ü µîÀ¸·Î ±¸ºÐµË´Ï´Ù. º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®Àº 2022³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¿ëµµº°·Î Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀåÀº Á¾¾çÇÐ, Æó, ½Å°æÇÐ, ½ÉÀåÇÐ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â¿¡´Â Á¾¾çÇÐ ºÐ¾ß°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î º¸¸é Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀåÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª ¹× ±âŸ Áß³²¹Ì·Î ±¸ºÐµË´Ï´Ù. ±âŸ Áß³²¹Ì°¡ 2022³â Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀåÀ» Á¡À¯À²À» µ¶Á¡Çß½À´Ï´Ù.

Rotem Industries Ltd, Invicro LLC, Cardinal Health Inc, Newcastle University, Novartis AG, Curium, IBA Radiopharma Solutions´Â Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå : ÁÖ¿ä »ê¾÷¿ªÇÐ

  • ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸¸¼º ÁúȯÀÇ À¯º´·ü »ó½Â
    • ÇÙ ¿µ»ó ±â¼úÀÇ ÀÌ¿ë Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¹æ»ç¼º Æ®·¹À̼­ÀÇ ÂªÀº »ç¿ë ±âÇÑ
    • ÇÙÀÇÇÐ ¿µ»ó Áø´Ü ÀýÂ÷ÀÇ ´ëüǰ À̿밡´É¼º
  • ½ÃÀå ±âȸ
    • ½ÅÈï °æÁ¦±¹ÀÇ Á¸Àç ¹× Àα¸ Áõ°¡
    • Ç¥Àû Ä¡·á¸¦ À§ÇÑ °³º°È­ ¹æ»ç¼º ÀǾàǰÀÇ °³¹ß
  • ÇâÈÄ µ¿Çâ
    • ¾Ï Áø´Ü¿¡¼­ ¹æ»ç¼º Æ®·¹À̼­ÀÇ »ç¿ë
  • ¿µÇ⠺м®

Á¦5Àå ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå : Áß³²¹Ì ½ÃÀå ºÐ¼®

  • ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀåÀÇ ¼öÀÍ(2022-2030³â)

Á¦6Àå Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå-¼öÀÍ ¹× ¿¹Ãø : Æ®·¹À̼­ À¯Çüº°(-2030³â)

  • ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå-¼öÀÍ Á¡À¯À²(%) : Æ®·¹À̼­ À¯Çüº°(2022³â, 2030³â)
  • Å×Å©³×Ƭ 99m ¹× TC-97m
  • ¿ä¿Àµå 131
  • ö 59
  • ·çÅׯ¬ 171
  • RB82 ¹× ¾Ï¸ð´Ï¾Æ N-13
  • ½ºÄ­µã 46
  • ½Ãº¸±â¿ò-269
  • ÇÖ½·-269
  • ±¸¿¬»ê °¥·ý GA67
  • PSMA GA68
  • FDDNP(F-18) ¹× FDOPA(f-18)
  • ÀÎ32 ¹× Å©·Ò-51
  • Å»·ý-201
  • F-18 FDG
  • F-18 FAPI
  • GA 68 FAPI
  • F-18 PSMA
  • DOTATOC/DOTANOC/DOTATATE GA 68
  • ±âŸ

Á¦7Àå Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå-¼öÀÍ ¹× ¿¹Ãø : °Ë»ç À¯Çüº°(-2030³â)

  • ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå-¼öÀÍ Á¡À¯À²(%) : °Ë»ç À¯Çüº°(2022³â, 2030³â)
  • PET
  • SPECT
  • ±âŸ

Á¦8Àå Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå-¼öÀÍ ¹× ¿¹Ãø : ¿ëµµº°(-2030³â)

  • ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå-¼öÀÍ Á¡À¯À²(%) : ¿ëµµº°(2022³â, 2030³â)
  • Á¾¾ç
  • Æó
  • ½Å°æÇÐ
  • ¼øÈ¯±â
  • ±âŸ

Á¦9Àå Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå-¼öÀÍ ¹× ¿¹Ãø : ÃÖÁ¾ »ç¿ëÀÚº°(-2030³â)

  • ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå-¼öÀÍ Á¡À¯À²(%) :ÃÖÁ¾ »ç¿ëÀÚº°(2022³â, 2030³â)
  • º´¿ø ¹× Áø·á¼Ò
  • Áø´Ü¼¾ÅÍ
  • Çмú±â°ü ¹× ¿¬±¸±â°ü
  • ±âŸ

Á¦10Àå Áß³²¹ÌÀÇ ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå : ±¹°¡º° ºÐ¼®

  • ºê¶óÁú
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ Áß³²¹Ì

Á¦11Àå ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀåÀÇ ¾÷°è Á¤¼¼

  • À¯±âÀû °³¹ß
  • ¹«±âÀû °³¹ß

Á¦12Àå ¹æ»ç¼º Æ®·¹À̼­ ½ÃÀå-ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Rotem Industries Ltd
  • Invicro LLC
  • Cardinal Health Inc
  • Newcastle University
  • Novartis AG
  • Curium
  • General Electric Co
  • IBA Radiopharma Solutions

Á¦13Àå ºÎ·Ï

AJY 24.02.15

The South & Central America radioactive tracer market was valued at US$ 476.96 million in 2022 and is expected to reach US$ 1,634.33 million by 2030; it is estimated to grow at a CAGR of 16.6% from 2022 to 2030.

Use of Radioactive Tracer in Cancer Diagnosis fuel the South & Central America Radioactive Tracer Market

Oncology is a significantly developing field in the healthcare sector, as cancer cases are increasing worldwide. According to Institute for Health Metrics and Evaluation (IHME), cancer is the second major cause of death after cardiovascular disorders. The use of advanced materials and drugs in the diagnosis and treatment of cancer has surged with prominent developments in oncology. Radioactive tracer-based imaging is one of the advanced diagnostic methods used to accurately diagnose cancer types, such as prostate cancer, gynecological cancer, and blood-borne cancer. Once injected into the body, these radioactive tracers attach to the cancer-specific sites, accurately diagnosing the cancer type. Tracer also helps determine the cancer development stage, enabling effective treatment and faster recovery in most cases. PET and SPECT are among the nuclear imaging techniques that use gamma emitters for detecting tumors. As the tumor grows, its uptake of the PET and SPECT conjugate increases over time, which improves contrast due to the presence of nuclear imaging agents. This further leads to blood clearance due to which clear diagnostic images can be generated. The most commonly used radioactive tracer for detecting cancer is F-18 fluorodeoxyglucose (18F-FDG), a compound similar to glucose or sugar. Cancer cells are highly active and need more energy, i.e., extra glucose, than normal cells. Imaging devices such as PET or SPECT detect this energy released by FDG to create an image showing the location of a radioactive tracer in the body. This helps determine the location of cancerous cells in the patient's body so that the treatment can be tailored according to the type and stage of cancer. Thus, the increasing use of radioactive tracer in cancer diagnostics is anticipated to drive market expansion during the estimated timeframe.

South & Central America Radioactive Tracer Market Overview

The South & Central America radioactive tracer market is segmented into Brazil, Argentina, and the Rest of South & Central America. The market in the region is expected to grow due to the increasing number of cancer cases, growing government initiatives, and rising research and development for radioactive tracer.

South & Central America Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Radioactive Tracer Market Segmentation

The South & Central America radioactive tracer market is segmented based on tracer type, test type, end user, application, and country. Based on tracer type, the South & Central America radioactive tracer market is segmented into technetium-99m & Tc-97m, iodine-131, iron-59, lutetium-171, rubidium (Rb-82) chloride & ammonia (N-13), scandium-46, seaborgium-269, hassium-269, Gallium citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), phosphorus-32 & chromium-51, thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and others. The others segment held the largest market share in 2022.

Based on test type, the South & Central America radioactive tracer market is segmented into PET, SPECT, and others. The PET segment held the largest market share in 2022.

Based on end user, the South & Central America radioactive tracer market is segmented into hospitals & clinics, diagnostic centers, academic & research institutes, and others. The hospitals & clinics segment held the largest market share in 2022.

Based on application, the South & Central America radioactive tracer market is segmented into oncology, pulmonary, neurology, cardiology, and others. The oncology segment held the largest market share in 2022.

Based on country, the South & Central America radioactive tracer market is segmented into Brazil, Argentina, and the Rest of South & Central America. The Rest of South & Central America dominated the South & Central America radioactive tracer market share in 2022.

Rotem Industries Ltd, Invicro LLC, Cardinal Health Inc, Newcastle University, Novartis AG, Curium, and IBA Radiopharma Solutions are some of the leading players operating in the South & Central America radioactive tracer market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America radioactive tracer market.
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the South & Central America radioactive tracer market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America radioactive tracer market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. South & Central America Radioactive Tracer Market - Key Industry Dynamics

  • 4.1 Key Market Drivers:
    • 4.1.1 Rising Prevalence of Chronic Diseases
    • 4.1.2 Increasing Use of Nuclear Imaging Techniques
  • 4.2 Market Restraints
    • 4.2.1 Short Shelf-Life of Radioactive Tracer
    • 4.2.2 Availability of Substitutes to Nuclear Diagnostic Imaging Procedures
  • 4.3 Market Opportunities
    • 4.3.1 Presence of Emerging Economies and Growing Population
    • 4.3.2 Development of Personalized Radiopharmaceuticals for Targeted Therapies
  • 4.4 Future Trends
    • 4.4.1 Use of Radioactive Tracer in Cancer Diagnosis
  • 4.5 Impact Analysis:

5. Radioactive Tracer Market - South & Central America Market Analysis

  • 5.1 Radioactive Tracer Market Revenue (US$ Mn), 2022 - 2030

6. South & Central America Radioactive Tracer Market - Revenue and Forecast to 2030 - by Tracer Types

  • 6.1 Overview
  • 6.2 Radioactive Tracer Market Revenue Share, by Tracer Types 2022 & 2030 (%)
  • 6.3 Technetium 99m and TC-97m
    • 6.3.1 Overview
    • 6.3.2 Technetium 99m and TC-97m: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Iodine 131
    • 6.4.1 Overview
    • 6.4.2 Iodine 131: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Iron 59
    • 6.5.1 Overview
    • 6.5.2 Iron 59: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.6 Lutetium- 171
    • 6.6.1 Overview
    • 6.6.2 Lutetium- 171: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.7 RB82 and ammonia N-13
    • 6.7.1 Overview
    • 6.7.2 RB82 and ammonia N-13: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.8 Scandium 46
    • 6.8.1 Overview
    • 6.8.2 Scandium 46: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.9 Seaborgium-269
    • 6.9.1 Overview
    • 6.9.2 Seaborgium-269: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.10 Hassium -269
    • 6.10.1 Overview
    • 6.10.2 Hassium -269: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.11 Gallium Citrate GA 67
    • 6.11.1 Overview
    • 6.11.2 Gallium Citrate GA 67: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.12 PSMA GA68
    • 6.12.1 Overview
    • 6.12.2 PSMA GA68: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.13 FDDNP (F-18) and FDOPA (f-18)
    • 6.13.1 Overview
    • 6.13.2 FDDNP (F-18) and FDOPA (f-18): Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.14 Phosphorus 32 and Chromium -51
    • 6.14.1 Overview
    • 6.14.2 Phosphorus 32 and Chromium -51: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.15 Thallium-201
    • 6.15.1 Overview
    • 6.15.2 Thallium-201: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.16 F-18 FDG
    • 6.16.1 Overview
    • 6.16.2 F-18 FDG: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.17 F-18 FAPI
    • 6.17.1 Overview
    • 6.17.2 F-18 FAPI: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.18 GA 68 FAPI
    • 6.18.1 Overview
    • 6.18.2 GA 68 FAPI: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.19 F-18 PSMA
    • 6.19.1 Overview
    • 6.19.2 F-18 PSMA: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.20 DOTATOC/DOTANOC/DOTATATE Ga 68
    • 6.20.1 Overview
    • 6.20.2 DOTATOC/DOTANOC/DOTATATE Ga 68: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.21 Others
    • 6.21.1 Overview
    • 6.21.2 Others: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)

7. South & Central America Radioactive Tracer Market - Revenue and Forecast to 2030 - by Test Type

  • 7.1 Overview
  • 7.2 Radioactive Tracer Market Revenue Share, by Test Type 2022 & 2030 (%)
  • 7.3 PET
    • 7.3.1 Overview
    • 7.3.2 PET: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 SPECT
    • 7.4.1 Overview
    • 7.4.2 SPECT: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Others
    • 7.5.1 Overview
    • 7.5.2 Others: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)

8. South & Central America Radioactive Tracer Market - Revenue and Forecast to 2030 - by Application.

  • 8.1 Overview
  • 8.2 Radioactive Tracer Market Revenue Share, by Application 2022 & 2030 (%)
  • 8.3 Oncology
    • 8.3.1 Overview
    • 8.3.2 Oncology: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Pulmonary
    • 8.4.1 Overview
    • 8.4.2 Pulmonary: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Neurology
    • 8.5.1 Overview
    • 8.5.2 Neurology: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Cardiology
    • 8.6.1 Overview
    • 8.6.2 Cardiology: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.7 Others
    • 8.7.1 Overview
    • 8.7.2 Others: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)

9. South & Central America Radioactive Tracer Market - Revenue and Forecast to 2030 - by End User

  • 9.1 Overview
  • 9.2 Radioactive Tracer Market Revenue Share, by End User 2022 & 2030 (%)
  • 9.3 Hospitals and Clinics
    • 9.3.1 Overview
    • 9.3.2 Hospitals and Clinics: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Diagnostic Centers
    • 9.4.1 Overview
    • 9.4.2 Diagnostic Centers: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Academic and Research Institutes
    • 9.5.1 Overview
    • 9.5.2 Academic and Research Institutes: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.6 Others
    • 9.6.1 Overview
    • 9.6.2 Others: Radioactive Tracer Market - Revenue and Forecast to 2030 (US$ Million)

10. South & Central America Radioactive Tracer Market - Country Analysis

  • 10.1 South & Central America Radioactive Tracer Market, Revenue and Forecast to 2030
    • 10.1.1 Overview
    • 10.1.2 South & Central America Radioactive Tracer Market by Country
      • 10.1.2.1 Brazil
        • 10.1.2.1.1 Overview
        • 10.1.2.1.2 Brazil Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.2.1.3 Brazil Radioactive Tracer Market, by Tracer Types
        • 10.1.2.1.4 Brazil Radioactive Tracer Market, by Test Type
        • 10.1.2.1.5 Brazil Radioactive Tracer Market, by Application
        • 10.1.2.1.6 Brazil Radioactive Tracer Market, by End-User
      • 10.1.2.2 Argentina
        • 10.1.2.2.1 Overview
        • 10.1.2.2.2 Argentina Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.2.2.3 Argentina Radioactive Tracer Market, by Tracer Types
        • 10.1.2.2.4 Argentina Radioactive Tracer Market, by Test Type
        • 10.1.2.2.5 Argentina Radioactive Tracer Market, by Application
        • 10.1.2.2.6 Argentina Radioactive Tracer Market, by End-User
      • 10.1.2.3 Rest of South & Central America
        • 10.1.2.3.1 Overview
        • 10.1.2.3.2 Rest of South & Central America Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.2.3.3 Rest of South & Central America Radioactive Tracer Market, by Tracer Types
        • 10.1.2.3.4 Rest of South & Central America Radioactive Tracer Market, by Test Type
        • 10.1.2.3.5 Rest of South & Central America Radioactive Tracer Market, by Application
        • 10.1.2.3.6 Rest of South & Central America Radioactive Tracer Market, by End-User

11. Radioactive Tracer Market Industry Landscape

  • 11.1 Overview
  • 11.2 Organic Developments
    • 11.2.1 Overview
  • 11.3 Inorganic Developments
    • 11.3.1 Overview

12. Radioactive Tracer Market, Key Company Profiles

  • 12.1 Rotem Industries Ltd
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Invicro LLC
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Cardinal Health Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Newcastle University
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Novartis AG
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Curium
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 General Electric Co
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 IBA Radiopharma Solutions
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦